Carol Karp - Prothena Plc Chief Regulatory Officer
| PRTA Stock | USD 16.01 4.06 33.97% |
Executive
Ms. Carol D. Karp is Chief Regulatory Officer of the Company, since 2016. Prior to joining Prothena, she was an independent regulatory consultant to biotechnology and pharmaceutical companies. From 2013 to 2014, Ms. Karp was Senior Vice President, Regulatory Affairs and Compliance at Esperion Therapeutics, Inc., and from 2010 to 2013, she was Vice President, Head of Global Regulatory Affairs, Pharmacovigilance Risk Management at Janssen Alzheimer Immunotherapy, a Johnson Johnson Company . Previously, Ms. Karp held senior regulatory positions at Janssen Alzheimer Immunotherapy, CV Therapeutics, Inc., PowderJect Technologies, VIVUS, Inc., Cygnus, Inc. and Janssen Pharmaceutica. She earned her BA in Biology from the University of Rochester, where she is a member of the Board of Trustees. since 2016.
| Age | 71 |
| Tenure | 8 years |
| Address | 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60 |
| Phone | 353 1 236 2500 |
| Web | https://www.prothena.com |
Prothena Plc Management Efficiency
The company has return on total asset (ROA) of (0.1566) % which means that it has lost $0.1566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.229) %, meaning that it created substantial loss on money invested by shareholders. Prothena Plc's management efficiency ratios could be used to measure how well Prothena Plc manages its routine affairs as well as how well it operates its assets and liabilities. As of December 20, 2024, Return On Tangible Assets is expected to decline to -0.22. In addition to that, Return On Capital Employed is expected to decline to -0.31. At present, Prothena Plc's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 16.1 M, whereas Total Assets are forecasted to decline to about 414.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Perrin BS | Nuvalent | N/A | |
| Eric MD | Pliant Therapeutics | 60 | |
| Sheila MD | Ventyx Biosciences | 54 | |
| Huw Nash | Stoke Therapeutics | 57 | |
| Paul Shin | 89bio Inc | N/A | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Anthony Casciano | Viridian Therapeutics | 47 | |
| Henry Pelish | Nuvalent | N/A | |
| Seth Harmon | Viridian Therapeutics | 44 | |
| PMP PEng | Oncolytics Biotech | N/A | |
| Mei Jang | Kiniksa Pharmaceuticals | N/A | |
| Amanda Kurihara | 89bio Inc | N/A | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Shiva Natarajan | 89bio Inc | 58 | |
| Matthew Metivier | Nuvalent | N/A | |
| Amy Levin | Oncolytics Biotech | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| Lily Hepworth | Immunocore Holdings | 41 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Ross Moat | Kiniksa Pharmaceuticals | 43 | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.16 |
Prothena plc Leadership Team
Elected by the shareholders, the Prothena Plc's board of directors comprises two types of representatives: Prothena Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prothena. The board's role is to monitor Prothena Plc's management team and ensure that shareholders' interests are well served. Prothena Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prothena Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hideki MD, Chief Officer | ||
| CPA CPA, Chief Controller | ||
| Jennifer Zibuda, Director Communication | ||
| Brandon Smith, Chief Officer | ||
| Wagner Zago, Chief Scientific Officer | ||
| Carol Karp, Chief Regulatory Officer | ||
| David Ford, Chief Officer | ||
| Chad Swanson, Chief Officer | ||
| Yvonne Tchrakian, Company Secretary | ||
| Michael Malecek, Chief Secretary | ||
| Mark CFA, Vice Relations | ||
| Karin CPA, Chief Controller | ||
| Tran MBA, CFO Officer | ||
| Gene Kinney, Chief Scientific Officer and Head of RandD |
Prothena Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prothena Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.99) % | ||||
| Operating Margin | (68.57) % | ||||
| Current Valuation | 135.25 M | ||||
| Shares Outstanding | 53.81 M | ||||
| Shares Owned By Insiders | 13.45 % | ||||
| Shares Owned By Institutions | 96.97 % | ||||
| Number Of Shares Shorted | 8.06 M | ||||
| Price To Earning | 37.12 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prothena plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Prothena Plc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prothena Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prothena Plc Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prothena plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. If investors know Prothena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prothena Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Revenue Per Share 2.482 | Quarterly Revenue Growth (0.99) | Return On Assets (0.16) | Return On Equity (0.23) |
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prothena Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prothena Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prothena Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.